TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30629473

Group type: EXPERIMENTAL
Intervention: MICRO (5-min bouts of moderate-intensity physical activity performed hourly for nine consecutive hours over 4 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ONE (single isoenergetic 45‐min bout of moderate‐intensity exercise)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SED (sedentary condition)
Number of subjects: 20
Study: 30557325

Group type: EXPERIMENTAL
Intervention: AZD1981
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27601419

Group type: EXPERIMENTAL
Intervention: Bromelain 3000 FIP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bromelain 4500 FIP
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bromelain (pooled treatments)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 1358498

Group type: EXPERIMENTAL
Intervention: Reduced glutathione (GSH) administration (1.2 g/day and 2.4 g/day intravenously)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chlordiazepoxide (initial dose 75‐100 mg/day)
Number of subjects: 24
Study: 21780962

Group type: EXPERIMENTAL
Intervention: Comprehensive educational group intervention
Number of subjects: 50
Study: 21076721

Group type: COMPARATOR
Intervention: 40 mg atorvastatin each night (Control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin 12 h before PCI (Low-load group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin 2 h to 4 h before PCI (Mid-load group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 60 mg atorvastatin 2 h to 4 h before PCI (High-load group)
Number of subjects: 80
Study: 18690806

Group type: EXPERIMENTAL
Intervention: rosuvastatin (RVS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 16308948

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current evidence about the impact of prostate cancer screening
Number of subjects: 0
Study: 12459075

Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.75 mg/kg) with abciximab
Number of subjects: 99

Group type: COMPARATOR
Intervention: Unfractionated heparin (70 U/kg) with abciximab
Number of subjects: 99
Study: 10506674

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (Social Work, CT)
Number of subjects: 135
Study: 8627826

Group type: EXPERIMENTAL
Intervention: Transrenal percutaneous papillotome incision under endoscopic guidance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transrenal percutaneous papillotome incision under fluoroscopic guidance
Number of subjects: 30
Study: 1932973

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day, adjusted between 5 and 40 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atenolol (50 mg/day, adjusted between 25 and 100 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 27

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 27
Study: 6660928

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (10 mg daily for 10 days, four times a year)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (50 mg for 10 days, four times a year)
Number of subjects: 35
Study: 30171777

Group type: EXPERIMENTAL
Intervention: Occlusal reduction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no occlusal reduction)
Number of subjects: 44
Study: 29411362

Group type: EXPERIMENTAL
Intervention: Forced coughing during cervical punch biopsy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no forced coughing)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Forced coughing during second biopsy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group during second biopsy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Forced coughing
Number of subjects: 90
Study: 26732419

Group type: EXPERIMENTAL
Intervention: NID 60/80 programming for VT/VF detection
Number of subjects: 60
Study: 24752196

Group type: EXPERIMENTAL
Intervention: Cephalic trim (CT) of the lateral crura
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Horizontal resection with cephalic hinged flap (HRCH) of the lateral crura
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Visual analog scale (VAS) for global nasal obstruction
Number of subjects: 52
Study: 23697214

Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: HD
Number of subjects: 92

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: CRF patients (both CAPD and HD)
Number of subjects: 92
Study: 19034051

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Genistein
Number of subjects: 389
Study: 22169947

Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (α(2)‐adrenergic receptor antagonist) administered 30 min before acquisition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol HCl (β‐adrenergic receptor antagonist) administered 90 min before selective reactivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol HCl administered after reactivation of the memory
Number of subjects: 0
Study: 15749141

Group type: EXPERIMENTAL
Intervention: Brief advice to stop smoking (Arm A)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Self-help manuals on three occasions (Arm B)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Interactive computer program three times in addition to Arm B (Arm C)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Standard care (Control not explicitly defined)
Number of subjects: 918
Study: 12042992

Group type: EXPERIMENTAL
Intervention: PTFE-covered nitinol stents
Number of subjects: 82
Study: 11382890

Group type: EXPERIMENTAL
Intervention: Chewing gum (N=21) from midnight until the end of the experiment
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standing/walking (N=27) for 15 minutes
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Chewing gum (N=60) for 15 minutes
Number of subjects: 151
Study: 8568287

Group type: EXPERIMENTAL
Intervention: bivalent live attenuated influenza A virus vaccine
Number of subjects: 50

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 50
Study: 1819976

Group type: EXPERIMENTAL
Intervention: LOPP (chlorambucil, vincristine, prednisone, procarbazine)
Number of subjects: 83

Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, prednisone)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: LOPP
Number of subjects: 83

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 83
Study: 7140133

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg IV propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.2 mg/kg oral propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg IV timolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg oral timolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29368622

Group type: EXPERIMENTAL
Intervention: Preschool Situational Self-Regulation Toolkit (PRSIST) program implemented by early childhood educators
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine practice (Control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PRSIST program
Number of subjects: 50
Study: 27646496

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 26553830

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 403
Study: 23973126

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: SF‐12 Mental Component Summary (MCS) score <40
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: SF‐12 Physical Component Summary (PCS) score <50
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Semi‐manual labour
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Manual labour
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: High maximum knee pain (4‐6 out of 10)
Number of subjects: 360
Study: 20835577

Group type: EXPERIMENTAL
Intervention: Aquatine Endodontic Cleanser (Aquatine EC) with EDTA rinse
Number of subjects: 45

Group type: COMPARATOR
Intervention: 6% sodium hypochlorite (NaOCl) with EDTA rinse
Number of subjects: 45
Study: 18157962

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 86
Study: 16024564

Group type: EXPERIMENTAL
Intervention: Down syndrome (DS) subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (DS and control)
Number of subjects: 20
Study: 14646609

Group type: EXPERIMENTAL
Intervention: Idazoxan (alpha-2 adrenoreceptor antagonist)
Number of subjects: 18
Study: 10383505

Group type: EXPERIMENTAL
Intervention: MK‐0966 250 mg q.d.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg t.d.s.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg q.d.s.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 8678131

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens 0.625 mg per day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conjugated estrogens 0.625 mg per day and medroxyprogesterone 2.5 mg per day
Number of subjects: 26
Study: 1874219

Group type: EXPERIMENTAL
Intervention: Propofol and alfentanil
Number of subjects: 57

Group type: COMPARATOR
Intervention: Thiopentone and alfentanil
Number of subjects: 57
Study: 6131487

Group type: EXPERIMENTAL
Intervention: Tardive dyskinesia (TD) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-tardive dyskinesia (NTD) group
Number of subjects: 0
Study: 31978815

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard antiemetic regimen
Number of subjects: 120
Study: 30037045

Group type: COMPARATOR
Intervention: 0 g of mixed spices
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 6 g of mixed spices
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 12 g of mixed spices
Number of subjects: 17
Study: 27109202

Group type: EXPERIMENTAL
Intervention: Surgeon-led, team-based model of strategies
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Routine patient change-over (Control)
Number of subjects: 1265
Study: 23508540

Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy plus polyglactin 910 mesh (vaginal)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paravaginal defect repair (abdominal)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 21924957

Group type: EXPERIMENTAL
Intervention: Color Me Healthy (CMH) curriculum
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (no CMH curriculum)
Number of subjects: 263
Study: 20033276

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention (audiovisual message)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 260
Study: 18724192

Group type: EXPERIMENTAL
Intervention: Facilitator supervision based on the Eban Theoretical Framework for Supervision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 16228125

Group type: EXPERIMENTAL
Intervention: Craniocervical junction decompression (CCJD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intrasyringeal CSF pulsatile motion
Number of subjects: 15
Study: 12537629

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 0
Study: 9708607

Group type: EXPERIMENTAL
Intervention: Falecalcitriol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 25
Study: 8551147

Group type: EXPERIMENTAL
Intervention: Sleep nasendoscopy (SN)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No sleep nasendoscopy (Control group A)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sleep nasendoscopy (SN) for palatal snorers
Number of subjects: 53
Study: 2223425

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 359255

Group type: EXPERIMENTAL
Intervention: Difunisal (250 mg or 500 mg twice daily for 5 days)
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Aspirin (600 mg four times daily for 5 days)
Number of subjects: 1902
Study: 31542737

Group type: EXPERIMENTAL
Intervention: Plan Well Guide decision aid administered to the patient by a facilitator with the SDM present.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plan Well Guide decision aid
Number of subjects: 90
Study: 28122933

Group type: EXPERIMENTAL
Intervention: Formula feeding (FF)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding <3 mo (EBF <3 mo)
Number of subjects: 728
Study: 25577661

Group type: COMPARATOR
Intervention: Consistent limb group (DTaP-IPV-Hib and PCV13 administered to the right leg)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Consistent limb group
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Alternating limb group (DTaP-IPV-Hib and PCV13 administered to alternating limbs)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 509
Study: 23714397

Group type: EXPERIMENTAL
Intervention: Dental awareness training for care coordinators plus a dental checklist for service users in addition to standard care
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 10
Study: 21292088

Group type: EXPERIMENTAL
Intervention: MSBR + HGF (intravenous 150 μg/kg per day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MSBR
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (sham operation)
Number of subjects: 45
Study: 18706460

Group type: EXPERIMENTAL
Intervention: End-tidal PCO2 measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous PCO2 measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paused breathing (hypoventilation)
Number of subjects: 0
Study: 17919488

Group type: EXPERIMENTAL
Intervention: 40 g oleic acid (FFA, 1830 kJ)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 g macadamia oil (TG, 1856 kJ)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 600 mL 4% milk protein (control, 352 kJ)
Number of subjects: 9
Study: 15490072

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy at a dose of 0.25 U/kg body weight/week for 72 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11876011

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, aqueous nasal spray, 400 micrograms per day, administered every 12 hours for 6 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 55
Study: 9697378

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide three times daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: 2% pilocarpine four times daily
Number of subjects: 81
Study: 8042862

Group type: EXPERIMENTAL
Intervention: Topical Acyclovir (ACV) plus 348U87, initiated immediately after UV exposure
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 2665093

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conservative-functional treatment with a newly developed shoe
Number of subjects: 20
Study: 798654

Group type: EXPERIMENTAL
Intervention: Daily occlusive applications of butylated hydroxytoluene for 60 days
Number of subjects: 16
Study: 31324213

Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (i-gel®)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Face mask ventilation
Number of subjects: 1150
Study: 29190604

Group type: EXPERIMENTAL
Intervention: Mulberry extract (300 mg/d, twice per day for 12 weeks)
Number of subjects: 60
Study: 25320864

Group type: EXPERIMENTAL
Intervention: Looming threat condition with high dispositional and comparative optimism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Looming threat condition with high dispositional but low comparative optimism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Looming threat condition
Number of subjects: 0
Study: 24296748

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (EXER), 60 min of cycling at 90% of the lactate threshold in the last 90 min of HD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Increased HD time of 30 min (TIME)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (EXER)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Routine care (CONT)
Number of subjects: 11
Study: 22088586

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Plantain and Senna Granule group
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Combination group (Acupuncture + Plantain and Senna Granule)
Number of subjects: 390
Study: 19318652

Group type: EXPERIMENTAL
Intervention: Assistance with pain treatment intervention
Number of subjects: 401

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 401
Study: 17373148

Group type: EXPERIMENTAL
Intervention: Cetaphil Moisturizing Cream applied twice daily for 15 days on one half of the face
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated side of the face
Number of subjects: 30
Study: 12609480

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily for 14 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (4 matched postmenopausal women without MPA treatment)
Number of subjects: 8
Study: 10713868

Group type: EXPERIMENTAL
Intervention: Routine pre-operative chest radiograph
Number of subjects: 6111
Study: 8622116

Group type: EXPERIMENTAL
Intervention: Isepamicin (15 mg/kg or 8 mg/kg once daily; 7.5 mg/kg twice daily; 4 mg/kg twice daily)
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Amikacin (7.5 mg/kg twice daily)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 1243
Study: 1708060

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 6218099

Group type: EXPERIMENTAL
Intervention: Mezlocillin (16 g daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Carbenicillin (30 g daily)
Number of subjects: 60
Study: 6742895

Group type: EXPERIMENTAL
Intervention: Intraarticular steroids
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mobilisations
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ice therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 42
Study: 30104867

Group type: EXPERIMENTAL
Intervention: High velocity resistance training (HVRT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Traditional resistance training (RT)
Number of subjects: 15
Study: 26923301

Group type: EXPERIMENTAL
Intervention: Irradiated RBC units with potassium adsorption filter (PAF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard blood infusion set (control)
Number of subjects: 30
Study: 24627988

Group type: EXPERIMENTAL
Intervention: Digital rotation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 30
Study: 22845178

Group type: EXPERIMENTAL
Intervention: Synchronous whole-body vibration at 35 Hz and 4 mm amplitude
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Side-alternating whole-body vibration at 26 Hz and 7.5 mm amplitude
Number of subjects: 10

Group type: COMPARATOR
Intervention: No vibrations
Number of subjects: 10
Study: 20130473

Group type: EXPERIMENTAL
Intervention: Connection domain mutations in HIV reverse transcriptase
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: A371V mutation
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Any CD mutation
Number of subjects: 345
Study: 18803951

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16010204

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo (anxiety)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo (insomnia)
Number of subjects: 391
Study: 12456419

Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 56
Study: 10353431

Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8547209

Group type: EXPERIMENTAL
Intervention: Ramipril (mean dose 8 mg)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 2025078

Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 units every 12 hours from the start of the operation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 7048826

Group type: EXPERIMENTAL
Intervention: Urokinase (200,000 Ploug units during the first 24 hours) followed by heparin (40,000 units daily for 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin (40,000 units daily for 6 days)
Number of subjects: 20
Study: 31163557

Group type: EXPERIMENTAL
Intervention: CO₂ laser
Number of subjects: 2

Group type: COMPARATOR
Intervention: Micro-flap surgery
Number of subjects: 2
Study: 28205258

Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 200 mg IV
Number of subjects: 10
Study: 26637583

Group type: EXPERIMENTAL
Intervention: 100 μg/mL of AMB nasal irrigation daily for 2 months
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normal saline (NS) solution nasal irrigation daily for 2 months
Number of subjects: 77
Study: 25543854

Group type: EXPERIMENTAL
Intervention: Web-based support (intervention group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 136